becatecarin

also known as Becatecarina · Becatecarine · BMS-181176 · BMY-27557 · Deae-rebeccamycin · NSC #655649 · Rebeccamycin Analogue · XL-119

Other / unclassified targets TOP1 via inhibition

Developed for: lymphoma · neuroblastoma · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · adult acute lymphoblastic leukemia · biliary tract cancer
+17 more
· blast phase chronic myelogenous leukemia, BCR-ABL1 positive · central nervous system neoplasm · childhood malignant neoplasm · chronic myelomonocytic leukemia · colorectal cancer · extrahepatic bile duct carcinoma · female breast carcinoma · gallbladder cancer · myelodysplastic syndrome with excess blasts · ovarian cancer · refractory anemia with excess blasts in transformation · renal cell carcinoma · retinoblastoma · sarcoma · small cell lung carcinoma · small intestine cancer · lung cancer
Investigated by: National Cancer Institute (NCI) · Barbara Ann Karmanos Cancer Institute · Case Comprehensive Cancer Center · Helsinn Healthcare SA · Memorial Sloan Kettering Cancer Center · Northwestern University

Trials 12 · a red edge is where a trial was stopped

today NCT00090025 · Ph 3 NCT00087204 · Ph 1 NCT00086983 · Ph 1 NCT00084487 · Ph 2 NCT00006262 · Ph 2 NCT00006102 · Ph 2 NCT00005027 · Ph 2 NCT00005817 · Ph 2 NCT00005085 · Ph 2 NCT00004189 · Ph 1 NCT00005997 · Ph 2 NCT00003737 · Ph 2

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT00087204	May 2004 → Jan 2007	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, inv(16)(p13.1;q22), acute myeloid leukemia, t(16;16)(p13.1;q22) +5	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00086983	May 2004 → Sep 2006	—	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT00004189	Oct 1999 → Jul 2003	lymphoma, small intestine cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 28 trials
Phase 2	NCT00084487	Apr 2004 → Apr 2008	small cell lung carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00006262	Jul 2000 → Sep 2001	ovarian cancer	Northwestern University	Terminated	No outcome recorded
Phase 2	NCT00006102	Jul 2000 → Jun 2006	central nervous system neoplasm, childhood malignant neoplasm, lymphoma, neuroblastoma +2	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00005027	Jun 2000 → Mar 2005	renal cell carcinoma	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00005817	Mar 2000 → May 2006	female breast carcinoma, male breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00005085	Feb 2000 → Jun 2002	colorectal cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00005997	Apr 1999 → Apr 2005	extrahepatic bile duct carcinoma, gallbladder cancer	Case Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00003737	Jan 1999 → Sep 2006	neuroblastoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT00090025	Sep 2004 → Nov 2006	biliary tract cancer	Helsinn Healthcare SA	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00006017 Comparator	May 2000 → Jul 2003	lung cancer	Case Comprehensive Cancer Center	Completed	No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	becatecarin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005817 ↗ 12 NCT00004189 ↗ NCT00006262 ↗ NCT00090025 ↗ NCT00006102 ↗ NCT00006017 ↗ NCT00005027 ↗ NCT00005997 ↗ NCT00084487 ↗ NCT00087204 ↗ NCT00003737 ↗ NCT00086983 ↗ NCT00005085 ↗
Known as	Becatecarina	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Known as	Becatecarine	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Known as	BMS-181176	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Known as	BMY-27557	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Known as	Deae-rebeccamycin	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Known as	NSC #655649	“BACKGROUND: Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity,...” PMID 17610262 ↗ Mar 2008
Known as	Rebeccamycin Analogue	“BACKGROUND: Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity,...” PMID 17610262 ↗ Mar 2008
Known as	XL-119	ChEMBL registry synonym — accepted as the source's own label CHEMBL2107313 ↗
Action	Inhibit	“topoisomerase inhibiting activity” PMID 17610262 ↗ Mar 2008 1 “DNA topoisomerase I inhibitor” CHEMBL2107313 ↗
Modality	Other / unclassified	“Rebeccamycin analogue (RA) is a novel antitumor antibiotic” PMID 19399502 ↗ Apr 2009
Route	Intravenous	“Patients receive rebeccamycin analogue IV over 1 hour” NCT00003737 ↗
Target	TOP1	“DNA topoisomerase I inhibitor” CHEMBL2107313 ↗